Amelotex rectal suppositories 15mg, 6pcs

Composition

Rectal suppositories are greenish-yellow, torpedo-shaped.

1 supp. meloxicam 15 mg

Excipients:

solid fat (Supposir BP) – 1628.5 mg,

macrogol glycerylhydroxystearate-16.5 mg

.3 pcs. – cell contour packages (2) – cardboard packs.

Pharmacological action

of NSAIDs, has anti-inflammatory, antipyretic, analgesic effects. Belongs to the class of oxycams; a derivative of enolic acid.

The mechanism of action is inhibition of Pg synthesis as a result of selective suppression of COX-2 enzymatic activity.

When prescribed in high doses, long-term use and individual characteristics of the body, COX 2 selectivity decreases.

Inhibits Pg synthesis in the inflammatory region to a greater extent than in the gastric mucosa or kidneys, which is associated with a relatively selective inhibition of COX-2. Less often causes erosive and ulcerative diseases of the gastrointestinal tract.

Indications

Inflammatory and degenerative joint diseases (osteoarthritis, osteoarthritis), rheumatoid arthritis, ankylosing spondylitis.

Contraindications

Acute peptic ulcer of the stomach and duodenum, severe liver function disorders, renal failure (without hemodialysis), pregnancy, children and adolescents under 15 years of age, hypersensitivity to meloxicam and other NSAIDs (including salicylates).

Side effects

From the digestive system: dyspepsia, nausea, vomiting, abdominal pain, constipation, intestinal colic, diarrhea, esophagitis, stomatitis; rarely-erosive and ulcerative lesions of the gastrointestinal tract.

From the central nervous system: dizziness, headache, tinnitus.

From the cardiovascular system: increased blood pressure, palpitations, swelling, hot flashes.

From the urinary system: changes in laboratory parameters of renal function.

From the hematopoietic system:  anemia, leukopenia, and thrombocytopenia.

Allergic reactions: bronchospasm, photosensitivity, pruritus, rash, urticaria.

Interaction

Concomitant use may reduce the effectiveness of antihypertensive drugs (beta-blockers, ACE inhibitors, vasodilators).

When used concomitantly with anticoagulants, the risk of bleeding increases.

Concomitant use with diuretics increases the risk of developing renal failure in patients in a state of dehydration.

When used concomitantly with NSAIDs, the risk of developing ulcerative lesions of the gastrointestinal tract and gastrointestinal bleeding increases.

When used concomitantly with lithium preparations, the concentration of lithium in the blood plasma increases.

When used concomitantly, colestyramine accelerates the elimination of meloxicam.

When used concomitantly with methotrexate, it is possible to increase the myelodepressive effect; with cyclosporine, it is possible to increase the nephrotoxic effect of cyclosporine.

How to take, course of use and dosage

Inside, with meals, in a daily dose of 7.5-15 mg. The maximum daily dose is 15 mg, in patients with severe renal insufficiency who are on hemodialysis – 7.5 mg.

With a slight or moderate decrease in renal function (creatinine clearance more than 25 ml/min), as well as with cirrhosis of the liver in a stable clinical condition, no dose adjustment is required. The initial dose in patients with an increased risk of side effects is 7.5 mg / day.

Rectally – 15 mg (one candle) 1 time a day.

Overdose

Not described

Special instructions

In case of peptic ulcers or gastrointestinal bleeding, the development of side effects from the skin and mucous membranes, the drug should be discontinued.

Patients with reduced BCC and reduced glomerular filtration rate (dehydration, CHF, cirrhosis of the liver, nephrotic syndrome, clinically expressed kidney diseases, diuretics, dehydration after major surgical operations) may develop clinically expressed CRF, which is completely reversible after discontinuation of the drug (in such patients, daily diuresis and renal function should be monitored at the beginning of treatment). With a persistent and significant increase in transaminases and changes in other parameters. For liver function indicators, the drug should be discontinued and follow-up tests should be performed.

In patients with an increased risk of side effects, treatment begins with a dose of 7.5 mg. In end-stage CRF in patients undergoing dialysis, the dose should not exceed 7.5 mg / day.

During the treatment period, care should be taken when driving vehicles and doing other activities. potentially dangerous activities that require increased concentration of attention and speed of psychomotor reactions (when dizziness and drowsiness occur).

To reduce the risk of gastrointestinal adverse events, the minimum effective dose should be used in the shortest possible course.

Product form

rectal suppositories

Active ingredient

Meloxicam

Conditions of release from pharmacies

By prescription

Dosage form

rectal suppositories

Description

For adults by doctor’s prescription, Children by doctor’s prescription, Children over 15 years of age

Indications

Sciatica, Rheumatoid Arthritis, Arthritis, Osteoarthritis, Sciatica, Osteochondrosis, Periarthritis, Lumbago, Osteoarthritis